Guanfacine for ADHD: A Psychiatrist’s Guide to Uses and Side Effects

Guanfacine is a non-stimulant medication in a class of drugs called centrally acting alpha-2A adrenergic agonists. It was developed decades ago to treat high blood pressure, and only later did researchers discover it could also support attention and impulse control. That history is the key to understanding the medication today, because guanfacine still carries its original blood pressure approval alongside its newer role in ADHD care.

A frequent question is whether guanfacine is a stimulant. It is not. Stimulant medications such as methylphenidate and amphetamine work mainly by increasing dopamine and norepinephrine activity, and they remain the first-line, most frequently prescribed ADHD medications. Guanfacine takes a different route entirely, which is part of why it can help individuals who do not respond well to stimulants, cannot tolerate their side effects, or need an additional medication alongside a stimulant.

Beyond ADHD, clinicians sometimes use guanfacine off-label for other concerns, including anxiety-related symptoms and tic disorders such as Tourette’s syndrome. Any such use is individualized and decided by a provider based on the full clinical picture.

Guanfacine is sold in two formulations, and the difference between them is the source of most of the confusion around this medication. They are not interchangeable, they are dosed differently, and they are FDA-approved for different things.

Immediate-release guanfacine, once sold under the brand name Tenex, is FDA-approved to treat high blood pressure in adults. It is the original form of the drug. The Tenex brand has been discontinued in the United States, but immediate-release guanfacine is still available as a generic. Its approved use is for blood pressure, not ADHD. When immediate-release guanfacine is prescribed for ADHD, in a child or an adult, that is an off-label use.

Extended-release guanfacine, sold as Intuniv, is the form developed and studied specifically for ADHD. It releases the medication gradually over the day, which is what makes once-daily dosing for attention and impulse control practical. Intuniv is FDA-approved to treat ADHD, and that approval is limited to children and adolescents ages 6 to 17. It can be used on its own or together with a stimulant; the FDA labeling specifically covers its use alongside stimulant medications, which underscores that the extended-release form is the one intended for ADHD.

Putting the two together makes the picture clear. The blood-pressure form (immediate-release, formerly Tenex) is FDA-approved only for hypertension. The ADHD form (extended-release Intuniv) is FDA-approved only for ADHD, and only in kids and teens ages 6 to 17. There is no version of guanfacine that the FDA has approved to treat ADHD in adults.

So why do clinicians prescribe it to adults at all? Because “off-label” does not mean unstudied or unsafe; it means the FDA approval process for that specific use was never completed. The ADHD trials behind Intuniv’s approval were conducted in children and adolescents, and the drug was never taken through the separate approval pathway for adult ADHD. At the same time, guanfacine is already FDA-approved in adults for high blood pressure, so its safety profile in adults is well established. That combination is why many providers are comfortable using guanfacine off-label, in either form, for adults with ADHD when it fits the clinical situation.

The brain region most closely tied to ADHD symptoms is the prefrontal cortex, the area responsible for working memory, impulse control, and the top-down regulation of attention and emotion. Guanfacine works by stimulating post-synaptic alpha-2A adrenergic receptors on the dendritic spines of neurons in this region. According to a translational review published in Neurobiology of Learning and Memory, this action strengthens the connectivity of prefrontal networks and enhances the cortex’s ability to do its job, which may help explain guanfacine’s effect on attention and impulse control.

The fact that guanfacine became an ADHD treatment at all is one of neuroscience’s frequently cited translational success stories, and much of the groundwork was laid at Yale. Beginning in the 1980s and 1990s, neuroscientist Dr. Amy Arnsten and colleagues studying how the prefrontal cortex supports working memory found that alpha-2A agonists could meaningfully improve cognitive performance in primates. A review of that work, published in the Yale Journal of Biology and Medicine, traces how those discoveries moved from the laboratory toward the clinic. Because ADHD involves weakened prefrontal regulation, researchers reasoned that targeting these same receptors could support attention and impulse control, and clinical trials in the 2000s bore that out, leading the FDA to approve extended-release guanfacine for ADHD.

Supporting evidence came from research on a widely used animal model of ADHD, in which guanfacine improved sustained attention and reduced overactivity and impulsiveness. It is worth noting that the exact mechanism of guanfacine in ADHD is still not fully understood, and it does not work the same way for everyone. What the evidence consistently suggests is that, rather than ramping up overall stimulation the way stimulants do, guanfacine supports the brain’s own regulatory circuitry.

For the right individual, guanfacine offers advantages that stimulants may not. It can be used on its own or as an add-on to a stimulant, and a clinical utility review in a peer-reviewed journal describes extended-release guanfacine as effective both as a monotherapy and as an adjunct to stimulant treatment in children and adolescents.

Potential benefits that clinicians and families often point to include:

• Reduced impulsivity and hyperactivity. Guanfacine may help reduce impulsive responses and excess motor activity, which are core features of ADHD for many individuals.
• A non-stimulant option. Because it is not a stimulant, guanfacine may be a useful choice when stimulants are not a good fit or when a family prefers a non-stimulant approach.
• Flexibility in how it is used. Guanfacine can serve as a standalone treatment for people who do not tolerate or respond to stimulants, or it can be combined with a stimulant to round out symptom coverage.
• Support around settling and sleep. The same calming quality that makes drowsiness a side effect can, for some individuals, help with the evening wind-down that often accompanies ADHD. Persistent sleep difficulties are worth raising with a provider, since the timing of a dose can make a difference.

Like any medication, guanfacine can also cause side effects, and they tend to reflect its origins as a blood pressure drug. According to the FDA prescribing information for guanfacine extended-release, the most commonly reported adverse reactions include somnolence, fatigue, insomnia, dizziness, and abdominal pain. Drowsiness and sedation are especially common and are among the most frequently cited reasons individuals stop the medication.

Other considerations a provider will weigh and monitor include:

• Effects on heart rate and blood pressure. Because guanfacine can lower blood pressure and slow heart rate, clinicians typically check these before starting, after dose changes, and periodically during treatment.
• Tapering rather than stopping abruptly. Stopping guanfacine suddenly can cause blood pressure to rebound, so the dose is usually reduced gradually under medical guidance.
• Swallowing extended-release tablets whole. Intuniv tablets should not be crushed or chewed, because breaking them changes how the drug is released.

A 2014 Phase III randomized controlled trial of extended-release guanfacine in children and adolescents found greater improvements in ADHD rating scores than placebo. Most treatment-emergent adverse events were mild or moderate, with somnolence, headache, and fatigue reported most commonly. The NIH LiverTox monograph on guanfacine similarly lists somnolence, sedation, headache, nausea, dizziness, low blood pressure, fatigue, and dry mouth among common side effects.

None of this is a substitute for individualized medical advice. Guanfacine is only prescribed when a clinician determines it is appropriate, and it should only be taken as and when prescribed, as part of ongoing medication management.

Guanfacine dosing is individualized and always set by a provider, but a few general patterns are useful to understand. The extended-release form (Intuniv) used for ADHD is taken once daily and is usually started at a low dose, then adjusted gradually based on response and tolerability. Because the medication builds up steadily rather than acting immediately, it can take a few weeks before its full effect on attention and impulsivity becomes clear.

As covered earlier, the extended-release form is FDA-approved for ADHD only in children and adolescents ages 6 to 17, and there is no FDA-approved guanfacine product for adult ADHD, so adult use of either form is off-label. Guanfacine tends to work best as part of a broader ADHD treatment plan that may also include therapy, skill-building, and other supports. For anyone still working out whether ADHD is the right explanation in the first place, an accurate ADHD evaluation is the foundation any medication decision should rest on.

Patience matters with this medication regardless of age. Stopping early because results are not immediate, or stopping abruptly without tapering, can work against the treatment. The most reliable path is steady follow-up with a provider who can fine-tune the dose and timing.

Guanfacine is a reminder that ADHD treatment is rarely one-size-fits-all. As a non-stimulant that supports prefrontal function, it gives providers a valuable option for individuals who cannot use stimulants, do not respond well to them, or need added support. The form matters: the extended-release version (Intuniv) is the one FDA-approved for ADHD, and only for children and teens, while adult use of guanfacine for ADHD is off-label in every form. Its benefits and its side effects both stem from the same underlying biology, which is exactly why medical supervision and an individualized plan matter so much.

Guanfacine is prescribed only when clinically appropriate and should only be taken as prescribed under the supervision of a licensed healthcare provider.